CD34+ fibrocytes in invasive ductal carcinoma, ductal carcinoma in situ, and benign breast lesions

Barth, Peter; Ebrahimsade, Schokufe; Ramaswamy, Annette; Moll, Roland

doi:10.1007/s004280100530

Cited by 119 publications

(135 citation statements)

References 20 publications

(30 reference statements)

Supporting

Mentioning

115

Contrasting

Unclassified

Order By: Relevance

“…19,21 In the stromal compartment of normal breast and benign and malignant breast lesions, the distribution of NGFR is strikingly similar to that described for CD34. 39,45,46 In fact, NGFR was consistently expressed by intralobular (myo)fibroblasts, stromal cells of benign biphasic neoplasms and in pseudoangiomatous stromal hyperplasias, but largely negative in the stromal compartment of invasive tumours. 39,45 Our findings corroborate those of Chauhan et al, 39 giving further evidence for the existence of more than one type of fibroblast in normal breast and in the stromal compartment of breast lesions.…”

Section: Discussionmentioning

confidence: 99%

Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue

et al. 2006

View full text Add to dashboard Cite

Nerve growth factor receptor (NGFR) is a transmembrane glycoprotein without intrinsic tyrosine kinase activity, whose expression is not restricted to neural cells. NGFR is reported to act as a tumour suppressor, negatively regulating cell growth and proliferation. NGFR expression was immunohistochemically analysed in normal breast tissue and in 140 benign, biphasic and preinvasive breast lesions, in 22 tumours with myoepithelial differentiation and in two cohorts of breast cancer patients: a series of 245 invasive breast carcinomas studied with tissue microarrays and 37 high-grade invasive ductal carcinomas with basal-like immunophenotype. NGFR consistently displayed membrane reactivity in myoepithelial cells arranged as a continuous layer around normal ducts and lobular units, intralobular fibroblasts, vascular adventitia and nerve bundles. Myoepithelial cells of benign proliferations and pre-invasive lesions were consistently positive for NGFR. Scattered NGFRpositive cells were observed in solid areas of six out of nine cases of hyperplasia of usual type, whereas in flat atypia, lobular carcinoma in situ and virtually all cases of ductal carcinoma in situ (97.5%), NGFR was restricted to the myoepithelial layer. Positivity for NGFR was observed in 11 out of 245 (4.5%) breast carcinomas, nine out of 20 (45%) metaplastic breast carcinomas and 14 out of 37 (38%) basal-like breast carcinomas. NGFR expression in invasive tumours significantly correlated with that of cytokeratins 5/6 (Po0.05), 14 (Po0.0001) and 17 (Po0.0005) and EGFR (Po0.0001) and displayed an inverse correlation with oestrogen and progesterone receptors (both, Po0.0001). NGFR showed a statistically significant association with longer disease-free (Po0.05) and overall survival (Po0.01) in the cohort of patients with basal-like carcinomas. This study demonstrates the usefulness of NGFR as a new adjunct marker to identify myoepithelial cells in preinvasive lesions and myoepithelial differentiation in breast carcinomas. Furthermore, provisional data in a small number of basal-like breast carcinomas suggest that NGFR may identify a subgroup of basal-like breast carcinomas with good prognosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue

et al. 2006

View full text Add to dashboard Cite

show abstract

“…+ fibrocytes (CD34 is a 110 kDa surface antigen selectively expressed on human haematopoietic progenitor cells) originating from myeloid precursors in the bone marrow were considered as a source of myofibroblasts in cancer of the colon [129], pancreas, [130], and breast [131]. Experimental studies have shown that CD34 + fibrocytes are attracted by the secondary lymphoid chemokine CCL-21, a ligand of the CCR7 chemokine receptor, and invade sites of tissue damage in vivo.…”

Section: The Origin Of Myofibroblastsmentioning

confidence: 99%

Role of tissue stroma in cancer cell invasion

Wever

Mareel

2003

The Journal of Pathology

923

813

View full text Add to dashboard Cite

show abstract

“…This study aimed to determine whether loss of CD34 is specific for invasive disease in the breast also (as has already been proved in other organs). An indication to this conclusion has been provided by some earlier researchers [11][12][13][14][15][16][17][18][19][20][21][22]. Bucala R et al also postulated that since CD34+ fibrocytes are capable of collagen I and collagen III synthesis, it seems to be likely that this cell type may be involved in the process of stromal remodeling in breast cancer [23].…”

Section: Introductionmentioning

confidence: 91%

“…"It has been suggested that there is an inverse relation between CD34 expression and myofibroblastic differentiation" [11].…”

Section: Introductionmentioning

confidence: 99%

A Clinicopathological Study of cd34 Antigen Expression in Benign and Malignant Breast Lesions

Khan¹,

Alam²,

Harris³

2017

J Clin Exp Pathol

View full text Add to dashboard Cite

Objectives: To study stromal CD34 expression in benign and malignant breast lesions and evaluate whether loss of CD34 is specific for invasive disease.Material and methods: 317 cases of benign and malignant breast lesions were studied over a period of 2 years (July 2012 to June 2014). All the cases underwent routine processing followed by H and E staining. 178 cases underwent CD34 immunohistochemical staining and semi quantitative assessment. Further, 74 cases of infiltrating ductal carcinoma were evaluated to determine relation of stromal CD34 expression with histological grade and lymph node metastasis.Results: Normal breast showed retained CD34 expression in 90.9% cases. Among benign lesions, 83% cases showed retained stromal CD34 expression (except cases of apocrine metaplasia, intraductal papilloma and fibroadenoma with focal atypia which showed reduced expression in 46.67%, 100% and 33.3% cases respectively). Both DCIS and LCIS showed reduced expression. Malignant tumors showed grade 0 staining in 97.9% cases, irrespective of the histological type. Statistically significant differences in stromal CD34 expression were observed between: Malignant phyllode`s tumor compared to its benign counterpart Papilloma and papillary carcinoma Benign and malignant lesions overall No significant correlation was found between CD34 expression and histological grade or lymph node metastasis. The metastatic foci in node positive patients showed a similar pattern of CD34 expression in the lymph nodes as those seen in the breast. Conclusion:Owing to the significant differences in CD34 expression between benign and malignant breast lesions, it can potentially be used to differentiate between the two and can serve as an important diagnostic marker. Further studies can also be undertaken to establish its role as a therapeutic target in cases of breast cancer.

show abstract

CD34+ fibrocytes in invasive ductal carcinoma, ductal carcinoma in situ, and benign breast lesions

Cited by 119 publications

References 20 publications

Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue

Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue

Role of tissue stroma in cancer cell invasion

A Clinicopathological Study of cd34 Antigen Expression in Benign and Malignant Breast Lesions

Contact Info

Product

Resources

About